Skip to main content
TipRanks
Go Ultimate75% OFF

Atrium Therapeutics, Inc. (RNA) Stock Statistics & Valuation Metrics

25 Followers

Total Valuation

Atrium Therapeutics, Inc. has a market cap or net worth of $162.00M. The enterprise value is -$32.45M.

Market Cap
$162.00M
Enterprise Value
-$32.45M

Share Statistics

Atrium Therapeutics, Inc. has 21,571,507 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
21,571,507
Owned by Insiders
2.21%
Owned by Institutions
31.56%

Financial Efficiency

Atrium Therapeutics, Inc.’s return on equity (ROE) is -0.37 and return on invested capital (ROIC) is -31.92%.

Return on Equity (ROE)
-0.37
Return on Assets (ROA)
-0.28
Return on Invested Capital (ROIC)
-31.92%
Return on Capital Employed (ROCE)
-0.32
Revenue Per Employee
36.43K
Profits Per Employee
-150.07K
Employee Count
511
Asset Turnover
0.07
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Atrium Therapeutics, Inc. is -1.83. Atrium Therapeutics, Inc.’s PEG ratio is 0.02.

PE Ratio
-1.83
PS Ratio
4.17
PB Ratio
0.62
Price to FCF
-1.95
Price to Operating Cash Flow
-1.61
PEG Ratio
0.02

Income Statement

In the last 12 months, Atrium Therapeutics, Inc. had revenue of 18.62M and earned -76.68M in profits. Earnings per share was -4.48.

Revenue
18.62M
Gross Profit
18.62M
Operating Income
-76.81M
Pretax Income
-76.83M
Net Income
-76.68M
EBITDA
-76.50M
Earnings Per Share (EPS)
-4.48

Cash Flow

In the last 12 months, operating cash flow was -79.69M and capital expenditures -3.43M, giving a free cash flow of -83.12M billion.

Operating Cash Flow
-79.69M
Free Cash Flow
-83.12M
Free Cash Flow per Share
-4.88

Dividends & Yields

Atrium Therapeutics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-51.31%
Earnings Yield
-69.68%

Stock Price Statistics

Beta
1.06
52-Week Price Change
-49.08%
50-Day Moving Average
8.78
200-Day Moving Average
11.92
Relative Strength Index (RSI)
32.73
Average Volume (3m)
291.45K

Important Dates

Atrium Therapeutics, Inc. upcoming earnings date is ―, After Close (Confirmed).

Last Earnings Date
Aug 13, 2026
Next Earnings Date
―
Ex-Dividend Date
―

Financial Position

Atrium Therapeutics, Inc. as a current ratio of 6.53, with Debt / Equity ratio of 1.77%

Current Ratio
6.53
Quick Ratio
6.53
Debt to Market Cap
0.00
Net Debt to EBITDA
3.48
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Atrium Therapeutics, Inc. has paid -142.00K in taxes.

Income Tax
-142.00K
Effective Tax Rate
0.00

Enterprise Valuation

Atrium Therapeutics, Inc. EV to EBITDA ratio is -1.30, with an EV/FCF ratio of -1.42.

EV to Sales
3.04
EV to EBITDA
-1.30
EV to Free Cash Flow
-1.42
EV to Operating Cash Flow
-1.48

Balance Sheet

Atrium Therapeutics, Inc. has $232.07M in cash and marketable securities with $679.00K in debt, giving a net cash position of $231.40M billion.

Cash & Marketable Securities
$232.07M
Total Debt
$679.00K
Net Cash
$231.40M
Net Cash Per Share
$10.73
Tangible Book Value Per Share
$12.03

Margins

Gross margin is 42.18%, with operating margin of -243.60%, and net profit margin of -229.67%.

Gross Margin
42.18%
Operating Margin
-243.60%
Pretax Margin
-229.58%
Net Profit Margin
-229.67%
EBITDA Margin
-233.35%
EBIT Margin
-235.84%

Analyst Forecast

The average price target for Atrium Therapeutics, Inc. is $21.25, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target
$21.25
Price Target Upside
182.96% Upside
Analyst Consensus
Strong Buy
Analyst Count
4
Revenue Growth Forecast
―
EPS Growth Forecast
―

Scores

Smart Score
8
AI Score
44